© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Dr Rafael Fonseca presents an overview of recent updates in the treatment of multiple myeloma and discusses strategies for incorporating the evidence into clinical practice.
June 1st 2022
Dr Rafael Fonseca, MD, provides insight on the evidence around quadruplet versus triplet therapies in patients with newly diagnosed, transplant-eligible multiple myeloma, and how to select the appropriate treatment regimen for this patient population.
June 8th 2022
Depth of response and treatment duration in patients with newly diagnosed MM are discussed by Dr Fonseca.
June 15th 2022
Rafael Fonseca, MD reviews the MAIA clinical trial and strategies for choosing the appropriate patients with transplant-ineligible newly diagnosed MM.
June 22nd 2022
Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.
June 29th 2022
Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.